TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

TG Therapeutics, Inc.NASDAQ: TGTX

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow grows, but more slowly than its trailing trend

Q3 FY2026 financing cash flow of $99.75M (cash outflow) rose 27.5% year over year, behind the +401.7% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +512.2% a year.

Context

  • Financing cash flow amounted to 14.6% of revenue in FY2025, down 24.5 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +27.5% toward the trailing-twelve-month pace of +401.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$99.75M-117447.1% QoQ
Last fiscal yearDec 2025
-$89.73M-169.8% YoY
LTMSep 2026
$292.23M+401.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.5%——
1 year-169.8%——
3-year CAGR+512.2%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(89.73M) USD
Year-over-year change
-169.8%

Financing Cash Flow vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +401.7% is the 3rd highest of 7, against a peer median of +278.6%.
  • Financing cash flow amounts to 32.6% of revenue for TGTX, versus a peer median of 191.0%.
TGTX Competitors
Financing Cash Flow for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$4.96B USD——120.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$327.45M USD+22878.8%-16.3%292364.3%
TGTXTG Therapeutics, Inc.LTM Sep 2026$292.23M USD+401.7%+512.2%32.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$226.9M USD+360.2%——
ADCTADC Therapeutics S.A.LTM Mar 2026$151.21M USD+55.9%—191.0%
MGNXMacroGenics, Inc.LTM Mar 2026$69.59M USD+16083.5%+247.3%44.3%
XNCRXencor, Inc.LTM Jun 2026$8.3M USD-95.9%+13.0%7.9%
IPHAInnate Pharma S.A.FY2025€5.83M EUR+197.0%—209.2%
ADAGAdagene Inc.LTM Jun 2024$2.15M USD—-37.1%264.1%
Peer median (excluding TGTX) —+278.6%-1.7%191.0%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(348.1M)(198.34M)12.67M23.38M447.18M
Depreciation & Amortization494K515K423K280K244K
Deferred Income Tax517K000(348M)
Stock-Based Compensation61.27M19.19M37.93M42.54M64.67M
Change in Working Capital(12.22M)(1.65M)(84.66M)(109.3M)(194.54M)
Accounts Receivables(1.39M)1.39M(51.09M)(78.09M)(176.44M)
Inventory(15.99M)0(36.94M)(66.85M)(33.45M)
Accounts Payables15.99M(11.01M)192K055.88M
Other Working Capital(10.83M)7.97M3.18M35.65M(40.52M)
Other Non-Cash Items2.4M4.11M2.22M2.58M5.67M
Operating Cash Flow(295.63M)(176.17M)(31.41M)(40.52M)(24.77M)
Capital Expenditures(401K)(14K)0(45K)(214K)
Acquisitions (Net)(69K)20M000
Purchases of Investments(55.53M)(107.27M)(146.88M)(311.89M)(223.49M)
Sales of Investments55.6M87.28M96.23M310.9M237.5M
Other Investing Activities69K(20M)000
Investing Cash Flow(332K)(20.01M)(50.65M)(1.04M)13.8M
Debt Repayment40M(975K)25M137.26M0
Common Stock Issued2.22M584K46.3M01.51M
Common Stock Repurchased000(8.76M)(91.24M)
Dividends Paid00000
Other Financing Activities(800K)01.41M25K0
Financing Cash Flow41.42M(391K)72.71M128.53M(89.73M)
Effect of Forex Changes00000
Net Change in Cash(254.55M)(196.57M)(9.36M)86.97M(100.7M)
Free Cash Flow(296.04M)(176.18M)(31.41M)(40.56M)(24.99M)

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.